Getinge AB (publ) GETI-B.ST
Nasdaq Stockholm · Healthcare · Medical Devices
277.80 SEK
−1.7%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Getinge
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 28,291 | 31,827 | 34,759 | 34,968 |
| EBITDA | 5,704 | 5,905 | 5,310 | 6,055 |
| Net income | 2,491 | 2,412 | 1,638 | 2,258 |
| Balance sheet | ||||
| Equity | 30,038 | 30,166 | 33,005 | 29,429 |
| Total debt | 5,824 | 8,076 | 10,727 | 10,884 |
| Cash | 5,676 | 2,728 | 2,961 | 3,401 |
| Net debt | 148 | 5,348 | 7,766 | 7,483 |
| Ratios and per share | ||||
| EBITDA margin | 20.2% | 18.6% | 15.3% | 17.3% |
| Profit margin | 8.8% | 7.6% | 4.7% | 6.5% |
| Return on equity | 8.3% | 8.0% | 5.0% | 7.7% |
| Earnings/share (SEK) | 9.15 | 8.86 | 6.01 | 8.29 |
| Book value/share (SEK) | 110.28 | 110.75 | 121.18 | 108.05 |
| Shares outstanding (M) | 272 | 272 | 272 | 272 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 33.5 |
| P/B | 2.6 |
| EV / EBITDA | 13.7 |
| Net debt / EBITDA | 1.2 |
| Return on equity | 7.7% |
| Profit margin | 6.5% |
| Beta 1Y | 0.75 |
| Revenue growth 1Y | +0.6% |
| Revenue CAGR 3Y | +7.3% |
| Earnings/share CAGR 3Y | −3.2% |
| ROE avg. 3Y | 6.9% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 4.75 |
| 2025 | 4.60 |
| 2024 | 4.40 |
| 2023 | 4.25 |
| 2022 | 4.00 |
Not investment advice. Figures may contain errors from the data source.